[Reposted from treatpeopleright.org] “Treating people right” means many things, but one of the things it means is that people living with and at risk of HIV/AIDS must have immediate and affordable access to new medicines, diagnostics, and other medical technologies…
In testimony before the U.S. House of Representatives Subcommittee on Intellectual Property, Competition and the Internet on 27 June 2012 (Hearing: Protecting Patents, Trade Secrets, and Market Access), the Deputy Director of the U.S. Patent and Trademark Office, who also serves…
Just as Novartis appealed from an order denying its patent application on Glivec, Bayer has now appealed the granting of a compulsory license on Nexavar. Rather than honestly state that it likes selling its cancer medicines for $67,000 to only…
Fifty AIDS activists, students, and community group members protested at Novartis’s Institute for BioMedical Research in Cambridge, Massachusetts, on February 22, the eve of the Swiss pharmaceutical company’s annual shareholders meeting in Berne Switzerland. The protest was part of two…
The Treatment Action Campaign has issued a Briefing providing a great summary of the campaign launched last year trying to convince/force the S. Africa government to adopt TRIPS-compliant flexibilities in its patent regime and thereafter to use them to increase access…